Logo image of VERU

VERU INC (VERU) Stock Fundamental Analysis

NASDAQ:VERU - Nasdaq - US92536C1036 - Common Stock - Currency: USD

0.4882  -0.02 (-4.27%)

Fundamental Rating

2

Overall VERU gets a fundamental rating of 2 out of 10. We evaluated VERU against 198 industry peers in the Pharmaceuticals industry. VERU has a bad profitability rating. Also its financial health evaluation is rather negative. VERU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VERU has reported negative net income.
VERU had a negative operating cash flow in the past year.
In the past 5 years VERU reported 4 times negative net income.
VERU had a negative operating cash flow in each of the past 5 years.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of VERU (-62.57%) is worse than 66.67% of its industry peers.
VERU's Return On Equity of -116.97% is on the low side compared to the rest of the industry. VERU is outperformed by 61.11% of its industry peers.
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 34.66%, VERU is in line with its industry, outperforming 57.07% of the companies in the same industry.
In the last couple of years the Gross Margin of VERU has declined.
The Profit Margin and Operating Margin are not available for VERU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERU has been increased compared to 1 year ago.
VERU has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VERU has been reduced compared to a year ago.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -6.57, we must say that VERU is in the distress zone and has some risk of bankruptcy.
VERU has a Altman-Z score of -6.57. This is in the lower half of the industry: VERU underperforms 66.16% of its industry peers.
VERU has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
VERU has a Debt to Equity ratio (0.27) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -6.57
ROIC/WACCN/A
WACC9.86%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

VERU has a Current Ratio of 2.97. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.97, VERU perfoms like the industry average, outperforming 53.54% of the companies in the same industry.
VERU has a Quick Ratio of 2.62. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.62, VERU is in line with its industry, outperforming 53.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.62
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.00% over the past year.
VERU shows a small growth in Revenue. In the last year, the Revenue has grown by 3.62%.
Measured over the past years, VERU shows a very negative growth in Revenue. The Revenue has been decreasing by -11.89% on average per year.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 1.30% on average over the next years.
VERU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 60.53% yearly.
EPS Next Y21.31%
EPS Next 2Y2.16%
EPS Next 3Y-6.33%
EPS Next 5Y1.3%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VERU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

A cheap valuation may be justified as VERU's earnings are expected to decrease with -6.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.16%
EPS Next 3Y-6.33%

More info and screens

0

5. Dividend

5.1 Amount

VERU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERU INC

NASDAQ:VERU (5/21/2025, 3:42:03 PM)

0.4882

-0.02 (-4.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners35.42%
Inst Owner Change-18.13%
Ins Owners10.62%
Ins Owner Change1.53%
Market Cap71.46M
Analysts81.82
Price Target2.72 (457.15%)
Short Float %12.56%
Short Ratio10.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.09%
Min EPS beat(2)-18.32%
Max EPS beat(2)20.51%
EPS beat(4)2
Avg EPS beat(4)-0.6%
Min EPS beat(4)-28.68%
Max EPS beat(4)24.1%
EPS beat(8)4
Avg EPS beat(8)3.01%
EPS beat(12)5
Avg EPS beat(12)-7.96%
EPS beat(16)8
Avg EPS beat(16)4.03%
Revenue beat(2)2
Avg Revenue beat(2)47.04%
Min Revenue beat(2)10.75%
Max Revenue beat(2)83.32%
Revenue beat(4)3
Avg Revenue beat(4)22.02%
Min Revenue beat(4)-41.15%
Max Revenue beat(4)83.32%
Revenue beat(8)4
Avg Revenue beat(8)1.72%
Revenue beat(12)6
Avg Revenue beat(12)-8.13%
Revenue beat(16)8
Avg Revenue beat(16)-3.95%
PT rev (1m)-3.03%
PT rev (3m)-21.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)4.42%
EPS NY rev (3m)16.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-57.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.23
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.81
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.12
BVpS0.22
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.66%
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.02%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.62
Altman-Z -6.57
F-Score4
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y21.31%
EPS Next 2Y2.16%
EPS Next 3Y-6.33%
EPS Next 5Y1.3%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%
EBIT growth 1Y61.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.36%
OCF growth 3YN/A
OCF growth 5YN/A